Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 17/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242792 | 0.81 | CYP2C9 (0.39) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| Sulfuric Acid SCHEMBL243166 | 0.68 | CPB2 (0.41) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL239158 | 0.66 | CPB2 (0.43) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL1402037 | 0.59 | CYP2C9 (0.58) | CPB2CYP2C9TSHRCYP2C19MTOR | |
| Hydrochloric Acid SCHEMBL3855530 | 0.58 | TDP1 (0.59) | CPB2CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL1402017 | 0.57 | CYP2C9 (0.55) | CPB2CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL27493546 | 0.57 | CYP2C9 (0.53) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL239541 | 0.56 | CYP2C9 (0.49) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL780302 | 0.56 | CA1 (0.64) | — | |
| SCHEMBL5294922 | 0.56 | CYP2C9 (0.56) | CPB2CPB1CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | CPB2 3120/4885CPB1 3681/4885CYP2C9 7/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | CPB2 3120/4885CPB1 3681/4885CYP2C9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.